
|Videos|April 11, 2014
Sequencing and Combining Idelalisib and Ibrutinib
Author(s)Anas Younes, MD
Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the prospect of sequencing or combining idelalisib and ibrutinib in lymphoid malignancies.
Advertisement
Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the prospect of sequencing or combining idelalisib and ibrutinib in lymphoid malignancies.
Clinical Pearls:
- Right now, there is no guidance on how to sequence the two agents
- Ibrutinib should not be given to patients on anticoagulation agents, such as Coumadin
- Side effect patterns will help physicians decide which agent a patient should receive
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Sacituzumab Govitecan Misses PFS in First-Line HR+/HER2– Metastatic Breast Cancer
2
First-in-Human Data Support Izalontamab in Advanced Epithelial Tumors
3
FDA Approves Subcutaneous Daratumumab for Smoldering Multiple Myeloma
4
Lurbinectedin and Tarlatamab in ES-SCLC
5








































